Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Highly selective, reversible inhibitor identified by comparative chemoproteomics modulates diacylglycerol lipase activity in neurons

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Baggelaar, M. P.
  • Chameau, P. J. P.
  • Kantae, V.
  • Hummel, J.
  • Hsu, K. L.
  • Janssen, F.
  • van der Wel, T.
  • Soethoudt, M.
  • Deng, H.
  • den Dulk, H.
  • Allara, M.
  • Florea, B. I.
  • Di Marzo, V.
  • Wadman, W. J.
  • Kruse, C. G.
  • Overkleeft, H. S.
  • Hankemeier, T.
  • Werkman, T. R.
  • Cravatt, Benjamin
  • van der Stelt, M.

publication date

  • July 2015

journal

  • Journal of the American Chemical Society  Journal

abstract

  • Diacylglycerol lipase (DAGL)-α and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion, but they are currently lacking. Here, we describe the identification of a highly selective DAGL inhibitor using structure-guided and a chemoproteomics strategy to characterize the selectivity of the inhibitor in complex proteomes. Key to the success of this approach is the use of comparative and competitive activity-based proteome profiling (ABPP), in which broad-spectrum and tailor-made activity-based probes are combined to report on the inhibition of a protein family in its native environment. Competitive ABPP with broad-spectrum fluorophosphonate-based probes and specific β-lactone-based probes led to the discovery of α-ketoheterocycle LEI105 as a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor. LEI105 did not affect other enzymes involved in endocannabinoid metabolism including abhydrolase domain-containing protein 6, abhydrolase domain-containing protein 12, monoacylglycerol lipase, and fatty acid amide hydrolase and did not display affinity for the cannabinoid CB1 receptor. Targeted lipidomics revealed that LEI105 concentration-dependently reduced 2-AG levels, but not anandamide levels, in Neuro2A cells. We show that cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model can be reduced by LEI105. Thus, we have developed a highly selective DAGL inhibitor and provide new pharmacological evidence to support the hypothesis that "on demand biosynthesis" of 2-AG is responsible for retrograde signaling.

subject areas

  • Animals
  • Cell Line
  • Drug Discovery
  • Enzyme Inhibitors
  • Heterocyclic Compounds
  • Hippocampus
  • Lipoprotein Lipase
  • Mice
  • Neurons
  • Synaptic Transmission
scroll to property group menus

Identity

PubMed Central ID

  • PMC4773911

International Standard Serial Number (ISSN)

  • 0002-7863

Digital Object Identifier (DOI)

  • 10.1021/jacs.5b04883

PubMed ID

  • 26083464
scroll to property group menus

Additional Document Info

start page

  • 8851

end page

  • 8857

volume

  • 137

issue

  • 27

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support